Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

INVESTIGATIONAL PRODUCT for Atrial fibrillation: Side Effects & Safety Data

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

There are 8 adverse event reports in the FDA FAERS database where INVESTIGATIONAL PRODUCT was used for Atrial fibrillation.

Most Reported Side Effects for INVESTIGATIONAL PRODUCT

Side Effect Reports % Deaths Hosp.
Febrile neutropenia 241 4.5% 29 215
Pneumonia 229 4.3% 69 209
Acute kidney injury 198 3.7% 35 185
Pyrexia 189 3.5% 17 171
Anaemia 176 3.3% 21 151
Diarrhoea 170 3.2% 28 131
Sepsis 168 3.1% 66 147
Dyspnoea 156 2.9% 26 124
Nausea 134 2.5% 14 93
Hypotension 130 2.4% 22 116
Vomiting 128 2.4% 15 99
Neutropenia 126 2.3% 16 68
Dehydration 113 2.1% 8 103
Fatigue 111 2.1% 18 77
Death 102 1.9% 102 33

Other Indications for INVESTIGATIONAL PRODUCT

Non-small cell lung cancer (288) Acute myeloid leukaemia (210) Product used for unknown indication (197) Malignant melanoma (181) Breast cancer (168) Plasma cell myeloma (151) Chronic lymphocytic leukaemia (104) Cardiac failure chronic (103) Neoplasm (101) Chronic obstructive pulmonary disease (89)

Other Drugs Used for Atrial fibrillation

RIVAROXABAN (52,584) DABIGATRAN ETEXILATE (20,492) APIXABAN (10,500) AMIODARONE (9,083) WARFARIN (8,680) EDOXABAN (3,855) ASPIRIN (2,993) DOFETILIDE (2,439) PRADAXA (2,325) METOPROLOL (1,542)

Related Pages

INVESTIGATIONAL PRODUCT Full Profile All Atrial fibrillation Drugs INVESTIGATIONAL PRODUCT Demographics INVESTIGATIONAL PRODUCT Timeline